Acanthe Développement Valuation

Q: What is the Fair Price of ACAN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

ACAN (€0.32) is trading below our estimate of [[fair value]] (€0.68)

Is ACAN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ACAN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ACAN (€0.32) is trading below our estimate of fair value (€0.68)

Significantly Below Fair Value: ACAN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ACAN?

Key metric: As ACAN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ACAN. This is calculated by dividing ACAN's market cap by their current revenue.
What is ACAN's PS Ratio?
PS Ratio	13.4x
Sales	€3.95m
Market Cap	€53.57m

ACAN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	10.9x
Enterprise Value/EBITDA	-5.1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ACAN's PS Ratio compare to its peers?

The above table shows the PS ratio for ACAN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	4.1x
MLORB Orbis Properties SOCIMI	3.9x	n/a	€66.0m
EIFF Société de la Tour Eiffel	0.7x	n/a	€80.0m
VTR Vitura	1.4x	n/a	€88.7m
MLINM Inmark Prime SocimiU	10.3x	n/a	€88.5m
ACAN Acanthe Développement	13.4x	n/a	€52.9m

Price-To-Sales vs Peers: ACAN is expensive based on its Price-To-Sales Ratio (13.4x) compared to the peer average (4.1x).

Price to Sales Ratio vs Industry

How does ACAN's PS Ratio compare vs other companies in the European Office REITs Industry?

3 Companies	Price / Sales	Estimated Growth	Market Cap

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: ACAN is expensive based on its Price-To-Sales Ratio (13.4x) compared to the European Office REITs industry average (8.2x).

Price to Sales Ratio vs Fair Ratio

What is ACAN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ACAN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	13.4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ACAN's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Healthcare Activos Yield SOCIMI

€245.6m

Operates as a real estate investment vehicle that focuses on the healthcare sector in Europe.

MLHAY

€1.41

4.4%

Faifey Invest Socimi

€98.7m

Invests in real estate assets in Spain.

MLECE

€19.50

20.4%

Paref

€60.3m

Owns and manages business real estate located primarily in the Paris region.

PAR

€40.00

-17.0%